A Phase II Study of Apatinib In Combination With Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2019
Price : $35 *
At a glance
- Drugs Etoposide (Primary) ; Rivoceranib (Primary)
- Indications Carcinoma; Ovarian cancer
- Focus Therapeutic Use
- 13 Jan 2019 Planned End Date changed from 1 Aug 2019 to 30 Jun 2019.
- 13 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 05 Jun 2018 Results (n=35) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.